publication date: Dec. 19, 2010

In this issue: 

NCI Director and Acting FDA Commissioner Andrew von Eschenbach endorses Rep. E. Clay Shaw in tour of Florida Congressman’s district. Von Eschenbach praises Shaw’s “leadership” in seeking funding for research, support of 2015 goal.

Shaw’s lung cancer, bronchoalveolar carcinoma, exemplifies elusiveness of 2015 goal. Little known about the rare disease.

Also in this 12-page issue: NCI to cut budgets for new grants by 29 percent. R01s to be funded at 11th percentile.

Download (PDF 821KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.